Pre-clinically, Higashikawa et al. labeled a murine CTLA-4 antibody with Cu64, 64Cu-DOTA-anti-CTLA-4, and evaluated its targeting in the CT26 tumor model, a syngeneic colon cancer model. Here, CTLA4 is linked to malignant colon neoplasm.